Literature DB >> 25329671

Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.

Kaniyampadi Sreenivasan Snima, Prathesha Pillai, Aleena Mary Cherian, Shantikumar V Nair, Vinoth-Kumar Lakshmanan1.   

Abstract

Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received tremendous recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anticancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem cell destruction along with cell cycle arrest and apoptosis induction are the proposed mechanisms of anticancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anticancer effect. It also focuses on the pharmacological applications of metformin and the nanotechnology approaches for metformin delivery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25329671     DOI: 10.2174/1568009614666141020105502

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

1.  Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation.

Authors:  Huimin Yan; Hui-Fang Zhou; Ying Hu; Christine T N Pham
Journal:  J Rheum Dis Treat       Date:  2015-02-28

Review 2.  Obesity and Cancer: An Angiogenic and Inflammatory Link.

Authors:  Dai Fukumura; Joao Incio; Ram C Shankaraiah; Rakesh K Jain
Journal:  Microcirculation       Date:  2016-04       Impact factor: 2.628

3.  Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.

Authors:  Muhammad Assad Riaz; Ali Sak; Yasin Bahadir Erol; Michael Groneberg; Jürgen Thomale; Martin Stuschke
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

4.  Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.

Authors:  Xuan Wei; Juanjuan Shi; Qianhan Lin; Xiaoxue Ma; Yingxin Pang; Hongluan Mao; Rui Li; Wei Lu; Yu Wang; Peishu Liu
Journal:  Front Oncol       Date:  2021-03-17       Impact factor: 6.244

5.  Phenformin Down-Regulates c-Myc Expression to Suppress the Expression of Pro-Inflammatory Cytokines in Keratinocytes.

Authors:  Guanyi Liu; Dingyang Li; Liwei Zhang; Qiuping Xu; Dexuan Zhuang; Panpan Liu; Ling Hu; Huiting Deng; Jianfeng Sun; Shuangshuang Wang; Bin Zheng; Jing Guo; Xunwei Wu
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

6.  Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.

Authors:  Vincent Kam Wai Wong; Hang Dong; Xu Liang; Li-Ping Bai; Zhi-Hong Jiang; Yue Guo; Ah Ng Tony Kong; Rui Wang; Richard Kin Ting Kam; Betty Yuen Kwan Law; Wendy Wen Luen Hsiao; Ka Man Chan; Jingrong Wang; Rick Wai Kit Chan; Jianru Guo; Wei Zhang; Feng Gen Yen; Hua Zhou; Elaine Lai Han Leung; Zhiling Yu; Liang Liu
Journal:  Oncotarget       Date:  2016-03-01

7.  Fyn phosphorylates AMPK to inhibit AMPK activity and AMP-dependent activation of autophagy.

Authors:  Eijiro Yamada; Shuichi Okada; Claire C Bastie; Manu Vatish; Yasuyo Nakajima; Ryo Shibusawa; Atsushi Ozawa; Jeffrey E Pessin; Masanobu Yamada
Journal:  Oncotarget       Date:  2016-11-15

8.  An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Authors:  Katherine M Bever; Erkut H Borazanci; Elizabeth A Thompson; Jennifer N Durham; Kimberly Pinero; Gayle S Jameson; Amber Vrana; Meizheng Liu; Cara Wilt; Annie A Wu; Wei Fu; Hao Wang; Yafu Yin; Jeffrey P Leal; Ana De Jesus-Acosta; Lei Zheng; Daniel A Laheru; Daniel D Von Hoff; Elizabeth M Jaffee; Jonathan D Powell; Dung T Le
Journal:  Oncotarget       Date:  2020-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.